Abstract
Sixteen patients with advanced melanoma received IFN-alpha 2A, 36 X 10(6) U/m2 i.m., on days 3-7 with 2.25 g/m2 DFMO p.o. on days 1-7. We observed no objective regressions. Median time to progression was 1.2 months with a median survival of 5.2 months. A flu-type syndrome was the predominant sequela. From the dose and schedule that we utilized, this regimen holds little promise against disseminated malignant melanoma.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Evaluation
-
Eflornithine / administration & dosage
-
Female
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Male
-
Melanoma / drug therapy*
-
Middle Aged
-
Recombinant Proteins / administration & dosage
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Eflornithine